There is a courageous little boy named Lev Kovalev. He’s just 7 years old, and he comes from Russia. Why do we call him brave? Here is his inspiring story.
Lev was diagnosed with neuroblastoma two years ago, a challenging cancer that had progressed despite initial treatments. His family was devastated when they learned about the bone marrow involvement and other complications shown in scans and biopsies. After exhausting options in local hospitals, including chemotherapy and surgery, the disease continued to advance, with signs of metastasis and low bone marrow activity. Desperate for a breakthrough, his parents sought advanced treatment abroad and discovered BIOOCUS, a leading center in cellular immunotherapy.
At BIOOCUS, Lev received personalized care from the start. Our international medical team provided a free evaluation based on his medical records, guiding the family through every step with compassion and expertise. Recognizing the potential of innovative therapies, we administered GD2 CAR-T cell therapy after preconditioning with fludarabine and cyclophosphamide. The process was seamless, thanks to our state-of-the-art facilities and dedicated support staff who ensured minimal discomfort for such a young patient. Post-infusion, Lev's CAR-T cells expanded effectively, reaching impressive levels by day 10 and beyond, leading to significant improvement in his condition. Follow-up MRI showed reduced tumor size and edema, marking a turning point in his battle.
What sets BIOOCUS apart is our commitment to high-quality service and cutting-edge products. Our CAR-T therapy targets specific markers like GD2, offering hope where traditional treatments fall short. The patient services team handled all logistics, from visa assistance to comfortable accommodations, making the experience stress-free for international families. Lev's family praises the multilingual support and round-the-clock care that made them feel at home.